Genetic test IDs at-risk hypertensive patients
Genetic test IDs at-risk hypertensive patients
Myriad Genetics Inc. in Salt Lake City has launched a new genetic test called CardiaRisk to help physicians identify which hypertensive patients are at a significantly increased risk of developing cardiovascular disease. The test also will identify which patients are likely to respond to low-salt diet therapy and antihypertensive drug therapy. It takes about two weeks to perform and costs $395.
CardiaRisk identifies patients with a greater risk of myocardial infarction (MI) and coronary disease by determining the presence of a genetic variation of the AGT gene. In a study of 422 patients, those with two copies of the variant AGT gene had a 2.6-times greater risk of coronary disease and a 3.4-times greater risk of MI. Hyper tensive patients with the variant gene are 43% more likely to progress, and their condition is more likely to occur earlier in life and become more severe.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.